BDBM311743 Ex. Cpd. 195::US10807986, Example 195::US11046696, Compound 195
SMILES COCc1ccc(NC(=O)c2c(C#Cc3cncc(c3)C#N)n(c3ncnc(N)c23)C2(C)CC2)cc1
InChI Key InChIKey=OQPFUWAMXGSTNL-UHFFFAOYSA-N
Data 9 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 9 hits for monomerid = 311743
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 1.10nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 3.80nMAssay Description:RET (V804M) (i.e., RET with V804M mutation) kinase activity was measured using purified recombinant human RET (V804M) protein purchased from Eurofins...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 3.80nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 3.80nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 0.300nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 1.10nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Taiho Pharmaceutical
US Patent
Taiho Pharmaceutical
US Patent
Affinity DataIC50: 1.10nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair